<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01800006</url>
  </required_header>
  <id_info>
    <org_study_id>16691</org_study_id>
    <secondary_id>XA1206</secondary_id>
    <nct_id>NCT01800006</nct_id>
  </id_info>
  <brief_title>Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region</brief_title>
  <acronym>XANTUS-EL</acronym>
  <official_title>XANTUS-EL, Xarelto® on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Noninterventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Belarus: Ministry of Health</authority>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <authority>Ecuador: Public Health Ministry</authority>
    <authority>Ecuador: Ethical Committee</authority>
    <authority>Egypt: Institutional Review Board</authority>
    <authority>Jordan: Ethical Committee</authority>
    <authority>Kazakhstan: Ethical Commission</authority>
    <authority>Kenya: Ethical Review Committee</authority>
    <authority>Kenya: Institutional Review Board</authority>
    <authority>Kenya: Ministry of Health</authority>
    <authority>Lebanon: Ministry of Public Health</authority>
    <authority>Lebanon: Institutional Review Board</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Peru: Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Saudi Arabia: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>United Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of Health</authority>
    <authority>Venezuela: Ministry of Health and Social Development</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This international study is a prospective noninterventional observational cohort study of
      patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine
      treatment conditions to prevent stroke or non-central nervous system systemic embolism.
      Patients will be followed up for 1 year or until 30 days after end of rivaroxaban therapy in
      case of therapy was discontinued earlier than 12 months. Serious adverse events will be
      followed up adequately. Laboratory values (e.g., Hb, HCT, haemoccult) should be documented
      for each point in time they were measured.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Adjudicated major bleeding events</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety variables will be summarized using descriptivestatistics based on adverse events collection</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated symptomatic thromboembolic events</measure>
    <time_frame>after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under
        routine treatment conditions to prevent stroke or noncentral nervous system systemic
        embolism.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial
             fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS
             systemic embolism, and who consent to participate in the study.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Azerbaijan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>ManyLocations</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kuwait</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>ManyLocations</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>ManyLocations</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Uruguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Venezuela</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Azerbaijan</country>
    <country>Bahrain</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Ecuador</country>
    <country>Egypt</country>
    <country>Georgia</country>
    <country>Jordan</country>
    <country>Kazakhstan</country>
    <country>Kenya</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Peru</country>
    <country>Qatar</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
    <country>Uruguay</country>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Observation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Embolism</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
